📝 Remedium Life — results explained
Quarter ended September 2025 (Q2 FY26)
Remedium Life reported revenue of ₹9 crore for the quarter ended September 2025 (Q2 FY26), down 65.8% from ₹25 crore in the same quarter last year, and down 53.3% sequentially over the June 2025 quarter.
Net profit fell 96.1% year-on-year to ₹0 crore, from ₹2 crore.
Operating profit stood at ₹-3 crore — an operating margin (OPM) of -34.8%, compared with 17.8% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY25, Remedium Life posted revenue of ₹222 crore, a decline of 94.5% over FY24, with a net profit of ₹2 crore (down 60.3% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹147 crore with a net loss of ₹2 crore.
Valuation snapshot
At the current price of ₹0.26, 539561 has a market capitalisation of ₹23 crore.
Within the Trading & Distributors industry, it is the 25th-largest of the 178 companies we track by market value.
Shareholding pattern
As of Dec 2025, promoters held 1.13%, foreign institutional investors (FIIs) 1.70%, public shareholders 97.17% of Remedium Life.